MA43518A - 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase - Google Patents

3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase

Info

Publication number
MA43518A
MA43518A MA043518A MA43518A MA43518A MA 43518 A MA43518 A MA 43518A MA 043518 A MA043518 A MA 043518A MA 43518 A MA43518 A MA 43518A MA 43518 A MA43518 A MA 43518A
Authority
MA
Morocco
Prior art keywords
azabicyclo
serving
hexanes
substituted
ketohexokinase
Prior art date
Application number
MA043518A
Other languages
English (en)
Other versions
MA43518B1 (fr
Inventor
Matthew Dowling
Dilinie Fernando
Kentaro Futatsugi
Kim Huard
Thomas Victor Magee
Brian Raymer
Andre Shavnya
Aaron Smith
Benjamin Thuma
Andy Tsai
Meihua Tu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA43518A publication Critical patent/MA43518A/fr
Publication of MA43518B1 publication Critical patent/MA43518B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)

Abstract

L'invention concerne des 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase, des procédés de fabrication de ces composés ainsi que des procédés comprenant l'administration desdits composés à un mammifère en ayant besoin.
MA43518A 2015-12-29 2016-12-16 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase MA43518B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562272598P 2015-12-29 2015-12-29
US201662423549P 2016-11-17 2016-11-17
PCT/IB2016/057728 WO2017115205A1 (fr) 2015-12-29 2016-12-16 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase

Publications (2)

Publication Number Publication Date
MA43518A true MA43518A (fr) 2018-11-07
MA43518B1 MA43518B1 (fr) 2021-05-31

Family

ID=57755415

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43518A MA43518B1 (fr) 2015-12-29 2016-12-16 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase

Country Status (39)

Country Link
US (6) US9809579B2 (fr)
EP (1) EP3397631B1 (fr)
JP (1) JP6503515B2 (fr)
KR (1) KR102073048B1 (fr)
CN (1) CN108473469B (fr)
AU (1) AU2016380920B2 (fr)
CA (1) CA2952466A1 (fr)
CL (1) CL2018001667A1 (fr)
CO (1) CO2018006714A2 (fr)
CU (1) CU24540B1 (fr)
CY (1) CY1124389T1 (fr)
DK (1) DK3397631T3 (fr)
EC (1) ECSP18048517A (fr)
ES (1) ES2871251T3 (fr)
GE (1) GEP20207147B (fr)
HK (1) HK1259073A1 (fr)
HR (1) HRP20210769T1 (fr)
HU (1) HUE054380T2 (fr)
IL (1) IL260330B (fr)
LT (1) LT3397631T (fr)
MA (1) MA43518B1 (fr)
MD (1) MD3397631T2 (fr)
MX (1) MX2018007755A (fr)
NI (1) NI201800072A (fr)
PE (1) PE20181289A1 (fr)
PH (1) PH12018501375A1 (fr)
PL (1) PL3397631T3 (fr)
PT (1) PT3397631T (fr)
RS (1) RS61896B1 (fr)
RU (1) RU2696269C1 (fr)
SG (1) SG11201804363UA (fr)
SI (1) SI3397631T1 (fr)
SV (1) SV2018005709A (fr)
TN (1) TN2018000198A1 (fr)
TW (1) TWI653232B (fr)
UA (1) UA121271C2 (fr)
UY (1) UY37051A (fr)
WO (1) WO2017115205A1 (fr)
ZA (1) ZA201803449B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201804363UA (en) * 2015-12-29 2018-07-30 Pfizer Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
IL292968A (en) 2016-09-02 2022-07-01 Cyclerion Therapeutics Inc scg motors in converging cycles
CN109316601B (zh) * 2017-07-31 2021-11-09 武汉朗来科技发展有限公司 药物组合物及其用途
TWI707683B (zh) 2018-06-13 2020-10-21 美商輝瑞股份有限公司 Ｇｌｐ－１受體促效劑及其用途
CR20210110A (es) 2018-08-31 2021-05-13 Pfizer Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas
TWI714231B (zh) * 2018-09-04 2020-12-21 美商美國禮來大藥廠 2,6-二胺基吡啶化合物
KR102558308B1 (ko) * 2018-09-27 2023-07-24 주식회사 엘지화학 3-아자바이사이클로[3,1,1]헵탄 유도체 및 이를 포함하는 약제학적 조성물
JP7248255B2 (ja) * 2019-01-29 2023-03-29 シャンドン スアンズ ファーマ カンパニー，リミテッド ヘキソングルコキナーゼ阻害剤およびその使用
CA3140972C (fr) 2019-05-20 2024-06-18 Pfizer Inc. Combinaisons comprenant du benzodioxol en tant qu'agonistes de glp-1r destinees a etre utilisees dans le traitement de la nash/nafld et de maladies associees
CN111978296A (zh) * 2019-05-22 2020-11-24 山东轩竹医药科技有限公司 己酮糖激酶抑制剂及其用途
JP2022534425A (ja) 2019-05-31 2022-07-29 イケナ オンコロジー， インコーポレイテッド Ｔｅａｄ阻害剤およびその使用
TWI750685B (zh) 2019-06-17 2021-12-21 美商美國禮來大藥廠 二取代吡唑化合物
KR20220112811A (ko) 2019-12-10 2022-08-11 화이자 인코포레이티드 2-((4-((S)-2-(5-클로로피리딘-2-일)-2-메틸벤조[d][1,3]디옥솔-4-일)피페리딘-1-일)메틸)-1-(((S)-옥세탄-2-일)메틸)-1H-벤조[d]이미다졸-6-카르복실산, 1,3-디히드록시-2-(히드록시메틸)프로판-2-아민 염의 고체 형태
US20230138901A1 (en) * 2019-12-24 2023-05-04 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Compound having khk inhibitory effect
CN114846008B (zh) * 2019-12-25 2024-05-28 杭州中美华东制药有限公司 具有果糖激酶(khk)抑制作用的嘧啶类化合物
GB202001856D0 (en) * 2020-02-11 2020-03-25 Inorbit Therapeutics Ab Compounds useful in inhibiting ketohexokinase and methods of making and using the same
US20230167087A1 (en) * 2020-02-13 2023-06-01 Eli Lilly And Company 2-[2-methylazetidin-1-yl]-4-phenyl-6-(trifluoromethyl)-pyrimidine compounds
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
US20230201185A1 (en) 2020-03-27 2023-06-29 Pfizer Inc. Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
JP2023522725A (ja) * 2020-04-20 2023-05-31 エルジー・ケム・リミテッド ３－アザビシクロアルキル誘導体およびこれを含む薬剤学的組成物
CN111423420A (zh) * 2020-04-30 2020-07-17 广州博济医药生物技术股份有限公司 作为己酮糖激酶抑制剂的并环化合物
CN113754640B (zh) * 2020-06-03 2023-02-14 山东轩竹医药科技有限公司 氘代的己酮糖激酶抑制剂及其用途
WO2022022476A1 (fr) * 2020-07-28 2022-02-03 山东轩竹医药科技有限公司 Forme de sel et forme cristalline d'un inhibiteur de cétohexokinase et utilisation associée
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
CN114181198A (zh) * 2020-09-15 2022-03-15 山东轩竹医药科技有限公司 嘧啶衍生物类己酮糖激酶抑制剂及其用途
EP4269404A1 (fr) * 2020-12-25 2023-11-01 Sichuan Haisco Pharmaceutical Co., Ltd. Inhibiteur de cétohexokinase et son utilisation
EP4313967A1 (fr) 2021-03-29 2024-02-07 Gilead Sciences, Inc. Inhibiteurs de khk
KR20220136939A (ko) 2021-04-01 2022-10-11 주식회사 엘지화학 옥사디아졸 화합물 및 이를 포함하는 약제학적 조성물
CN117677615A (zh) * 2021-06-17 2024-03-08 杭州中美华东制药有限公司 一种螺环化合物的盐型、晶型及其制备方法
EP4396182A1 (fr) 2021-08-31 2024-07-10 Pfizer Inc. Formes solides de sel de 1,3-dihydroxy-2-(hydroxyméthyl)propan-2-amine d'acide 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}pipéridin-1-yl)méthyl]-1-[(2s)-oxétan-2-ylméthyl]-1h-benzimidazole-6-carboxylique
WO2023061492A1 (fr) * 2021-10-14 2023-04-20 华领医药技术（上海）有限公司 Dérivé de 2-oxo-3-azabicyclo[3.1.0]hexane
WO2023111817A1 (fr) 2021-12-17 2023-06-22 Pfizer Inc. Formes cristallines d'acide [(1r,5s,6r)-3-{2-[(2s)-2-méthylazetidin-1-yl]-6-(trifluorométhyl) pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acétique
KR20230098069A (ko) 2021-12-24 2023-07-03 주식회사 엘지화학 (s)-2-(2-메틸아제티딘-1-일)피리미딘 유도체 및 이를 포함하는 약제학적 조성물
CN114315494B (zh) * 2021-12-29 2023-09-22 苏州楚凯药业有限公司 一种(s)-2-甲基氮杂环丁烷盐酸盐的制备方法
CN118679155A (zh) * 2022-02-09 2024-09-20 上海研健新药研发有限公司 一种khk抑制剂，其制备方法和应用
WO2023203135A1 (fr) 2022-04-22 2023-10-26 Precirix N.V. Anticorps radiomarqué amélioré
WO2023213801A1 (fr) 2022-05-02 2023-11-09 Precirix N.V. Pré-ciblage
WO2023228023A1 (fr) 2022-05-23 2023-11-30 Pfizer Inc. Traitement du diabète de type 2 ou contrôle de la gestion du poids avec de l'acide 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-méthylbenzo[d][1,3]dioxol-4-yl)pipéridin-1-yl)méthyl)-1-(((s)-oxétan-2-yl)méthyl)-1h-benzo[d]imidazole-6-carboxylique ou un sel pharmaceutique de celui-ci
WO2024084360A1 (fr) 2022-10-18 2024-04-25 Pfizer Inc. Modificateurs de la proteine 3 contenant le domaine phospholipase de type patatine (pnpla3)

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980350A (en) 1988-02-25 1990-12-25 Merck & Co., Inc. Piperazinylalkylpyrimidines as hypoglycemic agents
DE4208254A1 (de) 1992-03-14 1993-09-16 Hoechst Ag Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
IL140622A0 (en) 1998-07-06 2002-02-10 Bristol Myers Squibb Co Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
EP1383501B1 (fr) 2001-02-28 2007-04-04 Merck & Co., Inc. Derives de piperidine acyles utilises comme agonistes du recepteur de la melanocortin-4
EP1478437B1 (fr) 2002-02-27 2005-08-31 Pfizer Products Inc. Inhibiteurs de l'acetyl-coa-carboxylase
GEP20084421B (en) 2004-05-12 2008-07-10 Pfizer Prod Inc Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
JP4069159B2 (ja) 2004-05-25 2008-04-02 ファイザー・プロダクツ・インク テトラアザベンゾ［ｅ］アズレン誘導体及びそれらのアナログ
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
SI2463283T1 (sl) 2006-04-20 2014-09-30 Pfizer Products Inc. Kondezirane fenil amino heterociklične spojine za preprečevanje in zdravljenje bolezni, ki jih posreduje glukokinaza
US8933201B2 (en) 2006-06-07 2015-01-13 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
WO2008024902A2 (fr) 2006-08-23 2008-02-28 University Of Florida Research Foundation, Inc. Ciblage de fructokinase comme thérapie pour une maladie cardiovasculaire, un syndrome métabolique et une affection rénale
JP2010511035A (ja) 2006-11-29 2010-04-08 ファイザー・プロダクツ・インク スピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
WO2009049165A1 (fr) 2007-10-11 2009-04-16 Smithkline Beecham Corporation Inhibiteurs inédits de la seh et leur utilisation
ES2545231T3 (es) 2008-05-28 2015-09-09 Pfizer Inc. Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa
EP2297164A1 (fr) 2008-05-28 2011-03-23 Pfizer Inc. Inhibiteurs de la pyrazolospirocétone acétyl-coa carboxylase
CA2729581A1 (fr) 2008-07-29 2010-02-04 Pfizer Inc. Heteroaryles fluores
EP2326640A1 (fr) * 2008-07-30 2011-06-01 Ranbaxy Laboratories Limited Dérivés d'acide pyrrole carboxylique en tant qu'agents antibactériens
EA018492B1 (ru) 2008-08-28 2013-08-30 Пфайзер Инк. Диоксабицикло[3.2.1]октан-2,3,4-триольные производные
WO2010086820A1 (fr) 2009-02-02 2010-08-05 Pfizer Inc. Dérivés de 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazépin-6(5h)-yl)phényle
CA2754685A1 (fr) 2009-03-11 2010-09-16 Pfizer Inc. Indazole amides substitues
EP2406253B1 (fr) 2009-03-11 2013-07-03 Pfizer Inc. Dérivés de benzofuranyle utilisés comme inhibiteurs de la glucokinase
CA2754523A1 (fr) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3,3.1]nonanes
BRPI1014039A2 (pt) 2009-04-08 2018-04-03 Actelion Pharmaceuticals Ltd 6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas
JP2012526097A (ja) 2009-05-08 2012-10-25 ファイザー・インク Ｇｐｒ１１９調節因子
EP2427448A1 (fr) 2009-05-08 2012-03-14 Pfizer Inc. Modulateurs du gpr119
AU2010255422B2 (en) 2009-06-05 2014-04-10 Pfizer Inc. 1- ( piperidin-4-yl) -pyrazole derivatives as GPR 119 modulators
WO2011005611A1 (fr) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Agonistes du récepteur de la neuromédine u et leurs utilisations
KR101686913B1 (ko) 2009-08-13 2016-12-16 삼성전자주식회사 전자기기에서 이벤트 서비스 제공 방법 및 장치
US8822447B2 (en) * 2010-04-22 2014-09-02 Janssen Pharmaceutica Nv Indazole compounds useful as ketohexokinase inhibitors
US9387245B2 (en) 2010-08-06 2016-07-12 University Of Colorado, A Body Corporate Methods and compositions for the inhibition of fructokinase
CN102432598A (zh) * 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 三环化合物、其制备方法及其在医药上的应用
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
CN106103718B (zh) 2014-02-11 2021-04-02 阿尔尼拉姆医药品有限公司 己酮糖激酶(KHK)iRNA组合物及其使用方法
SG11201804363UA (en) * 2015-12-29 2018-07-30 Pfizer Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors

Also Published As

Publication number Publication date
US10787438B2 (en) 2020-09-29
JP2019500383A (ja) 2019-01-10
PT3397631T (pt) 2021-05-28
BR112018012047A2 (pt) 2018-12-04
CU24540B1 (es) 2021-08-06
NI201800072A (es) 2018-11-22
TWI653232B (zh) 2019-03-11
PE20181289A1 (es) 2018-08-07
US20200377482A1 (en) 2020-12-03
CL2018001667A1 (es) 2018-08-03
HRP20210769T1 (hr) 2021-06-25
US20170183328A1 (en) 2017-06-29
US20180037575A1 (en) 2018-02-08
AU2016380920A1 (en) 2018-06-14
SG11201804363UA (en) 2018-07-30
MA43518B1 (fr) 2021-05-31
LT3397631T (lt) 2021-06-10
US11634410B2 (en) 2023-04-25
GEP20207147B (en) 2020-09-10
MX2018007755A (es) 2018-11-09
SV2018005709A (es) 2018-09-10
US10988463B2 (en) 2021-04-27
UA121271C2 (uk) 2020-04-27
CO2018006714A2 (es) 2018-07-10
PL3397631T3 (pl) 2021-09-20
RS61896B1 (sr) 2021-06-30
AU2016380920B2 (en) 2019-10-31
EP3397631B1 (fr) 2021-04-07
US20200148669A1 (en) 2020-05-14
TW201726659A (zh) 2017-08-01
UY37051A (es) 2017-07-31
KR20180083427A (ko) 2018-07-20
IL260330B (en) 2021-07-29
ES2871251T3 (es) 2021-10-28
HUE054380T2 (hu) 2021-09-28
KR102073048B1 (ko) 2020-02-04
CN108473469B (zh) 2020-11-03
CY1124389T1 (el) 2022-07-22
JP6503515B2 (ja) 2019-04-17
EP3397631A1 (fr) 2018-11-07
TN2018000198A1 (en) 2019-10-04
US20190106412A1 (en) 2019-04-11
CN108473469A (zh) 2018-08-31
PH12018501375A1 (en) 2019-02-11
HK1259073A1 (zh) 2019-11-22
CU20180046A7 (es) 2018-09-05
US10174007B2 (en) 2019-01-08
RU2696269C1 (ru) 2019-08-01
SI3397631T1 (sl) 2022-01-31
MD3397631T2 (ro) 2021-08-31
US20210309644A1 (en) 2021-10-07
ECSP18048517A (es) 2018-07-31
IL260330A (en) 2018-08-30
ZA201803449B (en) 2019-02-27
DK3397631T3 (da) 2021-05-25
CA2952466A1 (fr) 2017-06-29
WO2017115205A1 (fr) 2017-07-06
US9809579B2 (en) 2017-11-07

Similar Documents

Publication Publication Date Title
MA43518B1 (fr) 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
CL2018002291A1 (es) Anticuerpos anti-fgfr2iiib afucosilados (divisional solicitud 201600221)
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
MA38959A1 (fr) Modulateurs du facteur b du complément
WO2015168635A3 (fr) Compositions et procédés pour moduler l'expression du facteur b du complément
UY36275A (es) Compuestos aminopirimidinilo
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
WO2016057683A3 (fr) Nouveaux anticorps anti-nodaux et méthodes d'utilisation de ceux-ci
MA38816A (fr) Sulfamidase modifiée et sa production
EA201990198A1 (ru) Радиолиганды для визуализации фермента ido1
EA201991863A1 (ru) Составы амфетамина, препятствующие злоупотреблению
EA201890186A1 (ru) Применение штаммов микробактерий для получения антибактериальных агентов
BR112017002675A2 (pt) métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila
EA201892235A1 (ru) Гранулированная композиция для перорального применения
WO2015109318A3 (fr) Méthodes thérapeutiques
MA39877A (fr) Formes solides d'un composé pharmaceutiquement actif
MX2020003554A (es) Moduladores de la expresion de enac.
RU2016108801A (ru) Пептид, обладающий лечебным действием против болезни Альцгеймера
FR3049582B1 (fr) Turbomachine, telle par exemple qu'un turboreacteur ou un turbopropulseur
MA39354A1 (fr) Compositions et procédés pour moduler l'expression du facteur b du complément
UA107468U (uk) 25,27-ди-(5-тіо-октилокси)калікс[4]арен-краун-6
MA38636A1 (fr) Composés de 3,4-dihydroisoquinoléin-2(1h)-yle